Dr. Lal PathLabs Q4 FY26 Revenue up 16.6% to ₹703 Cr, PAT at ₹132 Cr, declares 40% Dividend
Dr. Lal PathLabs reported Q4 FY26 consolidated revenue of ₹703 crore, up 16.6%. EBITDA grew 10.5% to a 26.6% margin. PAT was ₹132 crore (18.8% margin). A final dividend of 40% (₹4 per share) was declared. Cash and equivalents stood at ₹1,526 crore.
The results show healthy growth and profitability, which is positive for investors. The dividend payout further enhances shareholder returns.
The company reported strong revenue growth, improved profitability margins, and declared a dividend, indicating positive financial performance.
Dr. Lal PathLabs Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹703 crore for Q4 FY26, marking a growth of 16.6% compared to the same period in the previous fiscal year.
Consolidated EBITDA for Q4 FY26 increased by 10.5%, reaching a margin of 26.6%. The Profit After Tax (PAT) for the quarter stood at ₹132 crore, with a margin of 18.8%. The company also announced a final dividend of 40%, equivalent to ₹4 per share. As of March 31, 2026, Dr. Lal PathLabs maintained a healthy cash and cash equivalents balance of ₹1,526 crore.
As of March 31, 2026, Dr. Lal PathLabs operated a network comprising 312 clinical laboratories, including national and regional reference labs, along with 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs).
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.